Esaxerenone CAS 1632006-28-0

Introduction：Basic information about Esaxerenone CAS 1632006-28-0, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Esaxerenone Basic information

• Product Name: Esaxerenone
• Synonyms: cs3150;cs-3150;Esaxerenone;CS-3150(Esaxerenone;XL-550);CS-2614;5G,100G,500G;CS-3150; CS 3150; CS3150; XL-550; XL550; XL 550.
• CAS: 1632006-28-0
• MF: C22H21F3N2O4S
• MW: 466.48
• Mol File: 1632006-28-0.mol

Esaxerenone Chemical Properties

• Boiling point: 581.3±50.0 °C(Predicted)
• density: 1.35±0.1 g/cm3(Predicted)
• solubility: DMSO:100.0(Max Conc. mg/mL);214.37(Max Conc. mM)
• form: Solid
• pka: 12.76±0.70(Predicted)
• color: White to light yellow
• InChI: InChI=1S/C22H21F3N2O4S/c1-14-18(21(29)26-15-7-9-16(10-8-15)32(2,30)31)13-27(11-12-28)20(14)17-5-3-4-6-19(17)22(23,24)25/h3-10,13,28H,11-12H2,1-2H3,(H,26,29)
• InChIKey: NOSNHVJANRODGR-UHFFFAOYSA-N
• SMILES: C(N1C=C(C(=O)NC2C=CC(S(=O)(=O)C)=CC=2)C(C)=C1C1C=CC=CC=1C(F)(F)F)CO

Esaxerenone Usage And Synthesis

Uses

Esaxerenone, is a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.

Biological Activity

Esaxerenone exerts its antihypertensive effect by blocking excessive activation of the mineralocorticoid receptor by endogenous ligands (such as aldosterone), has a mineralocorticoid receptor selectivity at least 1000-fold greater than other steroid hormone receptors, a long half-life, high oral bioavailability, and has a more significant antihypertensive effect than spironolactone or eplerenone.

Synthesis

below shows the synthesis route of Esaxerenone

in vivo

After single oral administration of Esaxerenone at 0.1, 0.3, 1, and 3?mg/kg, maximum plasma concentration (C_max) and the area under the plasma concentration versus time curve (AUC) are increased with dose. Time to reach the maximum plasma concentration (T_max) of Esaxerenone ranges from 2.0 to 4.5?h. After intravenous administration of Esaxerenone at 0.1, 0.3, 1, and 3?mg/kg, the total body clearance (CL) and distribution volume at steady state (V_ss) are 3.53 to 6.69?mL/min/kg and 1.47 to 2.49?L/kg, respectively, in rats, and 2.79 to 3.69?mL/min/kg and 1.34 to 1.54?L/kg, respectively, in cynomolgus monkeys. Up to 168?h after administration, 3.9% and 91.4% of dosed radioactivity are excreted in rat urine and feces, respectively, and 95.2% in total. In monkeys, the excreted radioactivity up to 168?h is 11.5% in urine, 82.3% in feces, and 93.9% in total^[1].